Quarterly ResultAug 5, 2026, 04:17 PM
Vaxcyte Q2 Net Loss $284.3M; VAX-31 Phase 3 Data Q4 2026
AI Summary
Vaxcyte, Inc. announced its Q2 2026 financial results, reporting a net loss of $284.3 million and increased R&D expenses of $267.9 million. The company maintains a strong cash position of $2.5 billion and provided significant clinical pipeline updates. Key milestones include expected topline data from the VAX-31 adult Phase 3 OPUS-1 trial in Q4 2026 and the initiation of a Phase 1 study for VAX-A1, a Group A Strep vaccine candidate.
Key Highlights
- Net loss for Q2 2026 was $284.3 million, compared to $166.6 million in Q2 2025.
- R&D expenses for Q2 2026 increased to $267.9 million from $194.2 million in Q2 2025.
- Cash, cash equivalents, and investments totaled $2.5 billion as of June 30, 2026.
- Topline data from VAX-31 adult Phase 3 OPUS-1 trial expected in Q4 2026.
- Results from VAX-31 adult Phase 3 OPUS-2 and OPUS-3 trials expected in H1 2027.
- Topline data from VAX-31 infant Phase 2 study expected by end of H1 2027.
- Initiated Phase 1 study for VAX-A1; topline data expected in H2 2027.
- Appointed Dr. Moncef Slaoui and Dr. John Markels to the Board of Directors.
Price Impact
More from PCVX